Pricing Log in Create free account
Saturday 17 October 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.

18.66 0.44 +2.41%
Market cap
$20.9B
P/E
0.0×
Fwd P/E
61.1×
Dividend yield
2.57%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Viatris Inc. (VTRS) P/B ratio

Alert me on P/B ratio

As of 16 October 2026, Viatris Inc. (VTRS) trades at a P/B ratio of 1.5×. Over the past ten years it has ranged from 0.4× (March 2021) to 7.4× (March 2015); the current reading is higher than 71% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 1.8× and below the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 1.0× 24.27%
FY2024 0.8× 19.34%
FY2023 0.7× 2.05%
FY2022 0.7× (17.98%)
FY2021 0.8× 62.61%
FY2020 0.5× (43.73%)
FY2019 0.9× (24.72%)
FY2018 1.2× (33.09%)
FY2017 1.7× (4.06%)
FY2016 1.8× (30.97%)

Quarterly newest first

Period P/B ratio Change
Jun 2026 1.3× 21.65%
Mar 2026 1.1× 7.49%
Dec 2025 1.0× 30.77%
Sep 2025 0.8× 12.62%
42 more quarters

Against its own ten years

Low 0.4× High 7.4×
Ten-year median 0.8×
Current reading's percentile 78

P/B ratio against peers

Company P/B ratio
TAK Takeda Pharmaceutical Co. compare 1.3×
VTRS Viatris Inc. 1.5×
ELAN Elanco Animal Health Incorporated compare 1.8×
HLN Haleon PLC Sponsored ADR compare 2.1×
RDY Dr. Reddy's Laboratories Ltd compare 2.5×
UTHR United Therapeutics Corporation compare 3.5×
NBIX Neurocrine Biosciences, Inc. compare 3.7×
TEVA Teva Pharmaceutical Industries Ltd. compare 6.2×
ZTS Zoetis Inc. compare 10.5×
Drug Manufacturers Specialty & Generic industry median 1.8×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on VTRS